Study

▶ Beta blockers, selective are predicted to increase the risk of

peripheral vasoconstriction when given with

r

ergometrine.

Study

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the risk of ergotism when given with

r

ergometrine.

Theoretical

▶ Cobicistat is predicted to increase the risk of ergotism when

given with ergometrine. Avoid.rTheoretical

▶ Crizotinib is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Ergometrine is predicted to increase the risk of ergotism when

given with dopamine receptor agonists (cabergoline, pergolide).

Avoid.oTheoretical

1452 Enzalutamide — Ergometrine BNF 78

Interactions | Appendix 1

A1

▶ Esketamine is predicted to increase the risk of elevated blood

pressure when given with

Theoretical

ergometrine. Avoid.r

▶ Grapefruit juice is predicted to increase the exposure to

ergometrine.rTheoretical

▶ HIV-protease inhibitors are predicted to increase the risk of

ergotism when given with

Theoretical

ergometrine. Avoid.r

▶ Idelalisib is predicted to increase the risk of ergotism when

given with ergometrine. Avoid.rTheoretical

▶ Imatinib is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Ketamine is predicted to increase the risk of elevated blood

pressure when given with ergometrine.rTheoretical

▶ Letermovir is predicted to increase the concentration of

ergometrine. Avoid.rTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the risk of

ergotism when given with

Theoretical

ergometrine. Avoid.r

▶ Macrolides (erythromycin) are predicted to increase the risk of

ergotism when given with ergometrine.rTheoretical

▶ Netupitant is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Nilotinib is predicted to increase the risk of ergotism when

given with ergometrine.rTheoretical

▶ Ergometrine potentially increases the risk of peripheral

vasoconstriction when given with sympathomimetics, inotropic

(dopamine). Avoid.rAnecdotal

▶ Ergometrine is predicted to increase the risk of peripheral

vasoconstriction when given with sympathomimetics,

vasoconstrictor (noradrenaline/norepinephrine).rAnecdotal

Ergotamine

▶ Almotriptan is predicted to increase the risk of

vasoconstriction when given with ergotamine. Ergotamine

should be taken at least 24 hours before or 6 hours after

almotriptan.rTheoretical

▶ Antiarrhythmics (dronedarone) are predicted to increase the

risk of ergotism when given with ergotamine.rTheoretical

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the effects of

ergotamine.oTheoretical

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the risk of ergotism when given with

ergotamine.rTheoretical

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the risk of ergotism when given with

ergotamine. Avoid.rTheoretical

▶ Antifungals, azoles (miconazole) are predicted to increase the

exposure to ergotamine. Avoid.oTheoretical

▶ Aprepitant is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Beta blockers, non-selective are predicted to increase the risk

r

of peripheral vasoconstriction when given with ergotamine.

Study

▶ Beta blockers, selective are predicted to increase the risk of

peripheral vasoconstriction when given with

r

ergotamine.

Study

▶ Bosentan

o

is predicted to decrease the effects of ergotamine.

Theoretical

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the risk of ergotism when given with

r

ergotamine.

Theoretical

▶ Ceritinib is predicted to increase the exposure to ergotamine.

Avoid.rTheoretical

▶ Cobicistat is predicted to increase the risk of ergotism when

given with ergotamine. Avoid.rTheoretical

▶ Crizotinib is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Ergotamine is predicted to increase the risk of ergotism when

given with dopamine receptor agonists (bromocriptine,

cabergoline). Avoid.oTheoretical

▶ Ergotamine is predicted to increase the risk of ergotism when

Theoretical

given with dopamine receptor agonists (pergolide).o

▶ Efavirenz

o

is predicted to decrease the effects of ergotamine.

Theoretical

▶ Eletriptan increases the risk of vasoconstriction when given

with

Study

ergotamine. Separate administration by 24 hours.r

▶ Enzalutamide is predicted to decrease the effects of

ergotamine.oTheoretical

▶ Grapefruit juice is predicted to increase the exposure to

ergotamine.rTheoretical

▶ HIV-protease inhibitors are predicted to increase the risk of

ergotism when given with ergotamine. Avoid.rTheoretical

▶ Idelalisib is predicted to increase the risk of ergotism when

given with ergotamine. Avoid.rTheoretical

▶ Imatinib is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Letermovir is predicted to increase the concentration of

ergotamine. Avoid.rTheoretical

▶ Macrolides (clarithromycin) are predicted to increase the risk of

ergotism when given with ergotamine. Avoid.rTheoretical

▶ Macrolides (erythromycin) are predicted to increase the risk of

ergotism when given with ergotamine.rTheoretical

▶ Mitotane

o

is predicted to decrease the effects of ergotamine.

Theoretical

▶ Naratriptan is predicted to increase the risk of

vasoconstriction when given with ergotamine. Separate

administration by 24 hours.rTheoretical

▶ Netupitant is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Nevirapine

o

is predicted to decrease the effects of ergotamine.

Theoretical

▶ Nilotinib is predicted to increase the risk of ergotism when

given with ergotamine.rTheoretical

▶ Palbociclib is predicted to increase the exposure to

ergotamine. Adjust dose.oTheoretical

▶ Ribociclib (high-dose) is predicted to increase the exposure to

ergotamine. Avoid.oTheoretical

▶ Rifampicin

o

is predicted to decrease the effects of ergotamine.

Theoretical

▶ Rizatriptan is predicted to increase the risk of vasoconstriction

when given with ergotamine. Ergotamine should be taken at

least 24 hours before or 6 hours after

Theoretical

rizatriptan.r

▶ Rucaparib is predicted to increase the exposure to ergotamine.

Monitor and adjust dose.oStudy

▶ St John’s Wort is predicted to decrease the effects of

ergotamine.oTheoretical

▶ Sumatriptan increases the risk of vasoconstriction when given

with ergotamine. Ergotamine should be taken at least 24 hours

before or 6 hours after sumatriptan.rStudy

▶ Ticagrelor is predicted to increase the exposure to ergotamine.

Avoid.rTheoretical

Eribulin → see TABLE 15 p. 1378 (myelosuppression), TABLE 12 p. 1378

(peripheral neuropathy), TABLE 9 p. 1377 (QT-interval prolongation)

Erlotinib

FOOD AND LIFESTYLE Dose adjustment may be necessary if

smoking started or stopped during treatment.

▶ Antacids are predicted to decrease the absorption of erlotinib.

Antacids should be taken 4 hours before or 2 hours after

erlotinib.oTheoretical

▶ Antiarrhythmics (amiodarone, dronedarone) are predicted to

increase the exposure to erlotinib.oTheoretical

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy

▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)

are predicted to increase the exposure to

Theoretical

erlotinib.o ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to slightly increase the exposure to erlotinib. Use

with caution and adjust dose.oStudy

▶ Aprepitant

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Erlotinib is predicted to increase the risk of gastrointestinal

perforation when given with

Theoretical

aspirin (high-dose).r

BNF 78 Ergometrine — Erlotinib 1453

Interactions | Appendix 1

A1

Erlotinib (continued)

▶ Bosentan

r

is predicted to decrease the exposure to erlotinib.

Theoretical

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to

increase the exposure to erlotinib.oTheoretical

▶ Ciclosporin

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Cobicistat is predicted to slightly increase the exposure to

erlotinib. Use with caution and adjust dose.oStudy

▶ Combined hormonal contraceptives slightly increase the

exposure to

o

erlotinib. Monitor side effects and adjust dose.

Study

▶ Corticosteroids increase the risk of gastrointestinal

perforation when given with erlotinib.rTheoretical

▶ Erlotinib

r

increases the anticoagulant effect of coumarins.

Anecdotal

▶ Crizotinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Efavirenz

r

is predicted to decrease the exposure to erlotinib.

Theoretical

▶ Enzalutamide is predicted to decrease the exposure to

erlotinib. Avoid or adjust erlotinib dose, p. 979.rStudy

▶ Grapefruit juice is predicted to increase the exposure to

erlotinib.oTheoretical

▶ H2 receptor antagonists are predicted to decrease the exposure

to erlotinib. Erlotinib should be taken 2 hours before or

10 hours after H2 receptor antagonists.oStudy

▶ HIV-protease inhibitors are predicted to slightly increase the

exposure to

o

erlotinib. Use with caution and adjust dose.

Study

▶ Idelalisib is predicted to slightly increase the exposure to

erlotinib. Use with caution and adjust dose.oStudy

▶ Imatinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Lapatinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Macrolides (azithromycin, erythromycin) are predicted to

increase the exposure to erlotinib.oTheoretical

▶ Macrolides (clarithromycin) are predicted to slightly increase

the exposure to

o

erlotinib. Use with caution and adjust dose.

Study

▶ Mexiletine slightly increases the exposure to erlotinib. Monitor

side effects and adjust dose.oStudy

▶ Mitotane is predicted to decrease the exposure to erlotinib.

Avoid or adjust erlotinib dose, p. 979.rStudy

▶ Netupitant

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Nevirapine

r

is predicted to decrease the exposure to erlotinib.

Theoretical

▶ Nilotinib

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Erlotinib is predicted to increase the risk of gastrointestinal

perforation when given with NSAIDs.rTheoretical

▶ Erlotinib is predicted to increase the risk of bleeding events

when given with phenindione.rTheoretical

▶ Proton pump inhibitors are predicted to slightly decrease the

exposure to erlotinib. Avoid.oStudy

▶ Quinolones (ciprofloxacin) slightly increase the exposure to

erlotinib. Monitor side effects and adjust dose.oStudy

▶ Ranolazine

o

is predicted to increase the exposure to erlotinib.

Theoretical

▶ Rifampicin is predicted to decrease the exposure to erlotinib.

Avoid or adjust erlotinib dose, p. 979.rStudy

▶ SSRIs (fluvoxamine) are predicted to increase the exposure to

erlotinib

Theoretical

. Monitor side effects and adjust dose.o ▶ St John’s Wort is predicted to decrease the exposure to

erlotinib.rTheoretical

▶ Vemurafenib

o

is predicted to increase the exposure to erlotinib.

Theoretical

Ertapenem → see carbapenems

Ertugliflozin → see TABLE 14 p. 1378 (antidiabetic drugs), TABLE 8

p. 1376 (hypotension)

Erythromycin → see macrolides

Escitalopram → see SSRIs

Esketamine → see TABLE 8 p. 1376 (hypotension), TABLE 11 p. 1377 (CNS

depressant effects)

▶ Esketamine is predicted to increase the risk of seizures when

given with aminophylline. Avoid.rTheoretical

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to esketamine. Adjust dose.oTheoretical → Also see

TABLE 11 p. 1377

▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are

predicted to increase the exposure to

o

esketamine. Adjust dose.

Study

▶ Cobicistat is predicted to increase the exposure to esketamine.

Adjust dose.oStudy

▶ Enzalutamide is predicted to decrease the exposure to

esketamine. Adjust dose.oTheoretical

▶ Esketamine is predicted to increase the risk of elevated blood

pressure when given with

Theoretical

ergometrine. Avoid.r

▶ HIV-protease inhibitors are predicted to increase the exposure

to esketamine. Adjust dose.oStudy

▶ Idelalisib is predicted to increase the exposure to esketamine.

Adjust dose.oStudy

▶ Macrolides (clarithromycin) are predicted to increase the

exposure to esketamine. Adjust dose.oStudy

▶ Mitotane is predicted to decrease the exposure to esketamine.

Adjust dose.oTheoretical

▶ Rifampicin is predicted to decrease the exposure to

esketamine. Adjust dose.oTheoretical

▶ Esketamine is predicted to increase the risk of seizures when

given with theophylline. Avoid.rTheoretical

Eslicarbazepine → see antiepileptics

Esmolol → see beta blockers, selective

Esomeprazole → see proton pump inhibitors

Estramustine → see alkylating agents

Etanercept

▶ Anakinra is predicted to increase the risk of generalised

infection (possibly life-threatening) when given with

etanercept. Avoid.rTheoretical

▶ Live vaccines are predicted to increase the risk of generalised

infection (possibly life-threatening) when given with

etanercept. Public Health England advises avoid (refer to

Green Book).rTheoretical

Etelcalcetide

▶ Cinacalcet increases the risk of hypocalcaemia when given

with etelcalcetide. Avoid.rTheoretical

Ethambutol

▶ Isoniazid increases the risk of optic neuropathy when given

with ethambutol.rAnecdotal

Ethosuximide → see antiepileptics

Etodolac → see NSAIDs

Etomidate → see TABLE 8 p. 1376 (hypotension), TABLE 11 p. 1377 (CNS

depressant effects)

Etonogestrel

▶ Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin,

oxcarbazepine, perampanel, phenobarbital, phenytoin,

primidone, rufinamide, topiramate) are predicted to decrease

the efficacy of etonogestrel. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ Aprepitant is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Bosentan is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Efavirenz is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Fosaprepitant is predicted to decrease the efficacy of

etonogestrel. For FSRH guidance, see Contraceptives,

interactions p. 794.rTheoretical

▶ Griseofulvin decreases the efficacy of etonogestrel. For FSRH

guidance, see

Anecdotal

Contraceptives, interactions p. 794.r

1454 Erlotinib — Etonogestrel BNF 78

Interactions | Appendix 1

A1

▶ HIV-protease inhibitors (ritonavir) are predicted to decrease the

efficacy of etonogestrel. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ Modafinil is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Nevirapine is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Rifabutin is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ Rifampicin is predicted to decrease the efficacy of etonogestrel.

For FSRH guidance, see

r

Contraceptives, interactions p. 794.

Theoretical

▶ St John’s Wort is predicted to decrease the efficacy of

etonogestrel. MHRA advises avoid. For FSRH guidance, see

Contraceptives, interactions p. 794.rTheoretical

▶ Sugammadex is predicted to decrease the efficacy of

etonogestrel

Theoretical

. Use additional contraceptive precautions.r

▶ Ulipristal is predicted to decrease the efficacy of etonogestrel.

Avoid.rTheoretical

Etoposide → see TABLE 15 p. 1378 (myelosuppression)

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the efficacy of

etoposide.oStudy

▶ Ciclosporin increases the exposure to etoposide. Monitor and

adjust dose.rStudy

▶ Live vaccines are predicted to increase the risk of generalised

infection (possibly life-threatening) when given with

etoposide. Public Health England advises avoid (refer to Green

Book).rTheoretical

▶ Netupitant

o

slightly increases the exposure to etoposide.

Study

Etoricoxib → see NSAIDs

Etravirine

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,

phenytoin, primidone) are predicted to decrease the exposure

to etravirine. Avoid.rTheoretical

▶ Etravirine

o

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more